{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:24:10Z","timestamp":1791491050170,"version":"4.3.4"},"reference-count":38,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"King Saud University, Riyadh, Saudi Arabia","award":["RSP2023R16"],"award-info":[{"award-number":["RSP2023R16"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Background: Belimumab use for the management of systemic lupus erythematosus (SLE) has been limited, in part due to its high acquisition cost relative to the standard of care (SoC) and the uncertainties about its cost-effectiveness. Therefore, the aim of this study was to compare the cost and effectiveness of belimumab versus the SoC alone for the management of SLE using real-world data from the perspective of public healthcare payers in Saudi Arabia. Methods: Data were retrieved from a national prospective cohort of SLE, Saudi Arabia. Adult SLE patients (\u226518 yrs.) treated with belimumab plus the SoC or the SoC alone for at least six months were recruited. The effectiveness was measured using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). Unit costs for health services and prescription drugs were retrieved from the Saudi ministry of health. Nonparametric bootstrapping with inverse probability weighting was conducted to generate the 95% confidence limits for the cost and effectiveness. Results: A total of 15 patients on belimumab plus the SoC and 41 patients on the SoC alone met the inclusion criteria and were included in the analysis. The majority of patients were females (91.07%) with a mean age of 38 years. The mean difference in cost and SLEDAI-2K score reduction between belimumab versus the SoC were USD 5303.16 [95% CI: USD 2735.61\u2013USD 7802.52] and 3.378 [95% CI: 1.769\u20136.831], respectively. Belimumab demonstrated better effectiveness but higher cost in 96% of the bootstrap cost-effectiveness distributions. Conclusion: Future studies should use more robust research designs and a larger sample size to confirm the findings of this study.<\/jats:p>","DOI":"10.3390\/ijerph20031917","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T02:35:55Z","timestamp":1674182155000},"page":"1917","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cost Consequence Analysis of Belimumab versus Standard of Care for the Management of Systemic Lupus Erythematosus in Saudi Arabia: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2131-0094","authenticated-orcid":false,"given":"Aseel","family":"Alsuwayegh","sequence":"first","affiliation":[{"name":"Corporate Department of Pharmacy Services, King Saud University Medical City, Riyadh 11451, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8176-287X","authenticated-orcid":false,"given":"Ibrahim A.","family":"Almaghlouth","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2097-3534","authenticated-orcid":false,"given":"Majed Ali","family":"Almasaoud","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Sulaiman","family":"Alzaid","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2113-3430","authenticated-orcid":false,"given":"Adel Abdulaziz","family":"Alsuhaibani","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyan Hassan","family":"Almana","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Mohammed","family":"Alabdulkareem","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joud Abdullah","family":"Abudahesh","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0029-5924","authenticated-orcid":false,"given":"Yazed","family":"AlRuthia","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia"},{"name":"Pharmacoeconomics Research Unit, Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"A277","DOI":"10.1016\/j.autrev.2009.12.008","article-title":"The geoepidemiology of systemic lupus erythematosus","volume":"9","author":"Borchers","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"ref_2","first-page":"330","article-title":"Manifestations of systemic lupus erythematosus","volume":"6","author":"Cojocaru","year":"2011","journal-title":"Maedica"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ncl.2009.09.004","article-title":"Neurologic manifestations of systemic lupus erythematosus in children and adults","volume":"28","author":"Muscal","year":"2010","journal-title":"Neurol. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1002\/1529-0131(199912)42:12<2682::AID-ANR26>3.0.CO;2-6","article-title":"Patterns of disease activity in systemic lupus erythematosus","volume":"42","author":"Barr","year":"1999","journal-title":"Arthritis Rheum."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1177\/0961203318786436","article-title":"SLE mortality remains disproportionately high, despite improvements over the last decade","volume":"27","author":"Singh","year":"2018","journal-title":"Lupus"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.berh.2018.09.004","article-title":"Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus","volume":"32","author":"Gergianaki","year":"2018","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10067-010-1509-0","article-title":"Quality of life and satisfaction with life in SLE patients-the importance of clinical manifestations","volume":"29","author":"Kulczycka","year":"2010","journal-title":"Clin. Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s12016-017-8640-5","article-title":"Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus","volume":"55","author":"Bakshi","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJMe2208772","article-title":"Progress toward Better Treatment of Lupus","volume":"387","author":"Wallace","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40744-020-00212-9","article-title":"Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New","volume":"7","author":"Basta","year":"2020","journal-title":"Rheumatol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1177\/09612033221079771","article-title":"Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: A regulatory perspective","volume":"31","author":"Liu","year":"2022","journal-title":"Lupus"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"A117","DOI":"10.1016\/j.jval.2013.03.564","article-title":"Estimating the cost-effectiveness of belimumab versus standard care for sle patients in Hong Kong","volume":"16","author":"Lee","year":"2013","journal-title":"Value Health"},{"key":"ref_16","first-page":"161","article-title":"Cost-effectiveness analysis of Belimumab in patients with systemic lupus erythematosus in Spain","volume":"39","author":"Parrondo","year":"2015","journal-title":"Farm. Hosp."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2215\/CJN.13030921","article-title":"The Cost-Effectiveness of Belimumab and Voclosporin for Patients with Lupus Nephritis in the United States","volume":"17","author":"Mandrik","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e26704","DOI":"10.1097\/MD.0000000000026704","article-title":"National systemic lupus erythematosus prospective cohort in Saudi Arabia: A study protocol","volume":"100","author":"Almaghlouth","year":"2021","journal-title":"Medicine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/acr.24221","article-title":"Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage","volume":"72","author":"Arora","year":"2020","journal-title":"Arthritis Care Res."},{"key":"ref_20","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J. Rheumatol."},{"key":"ref_21","first-page":"S99","article-title":"Assessing remission in systemic lupus erythematosus","volume":"24","author":"Mosca","year":"2006","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_22","first-page":"360","article-title":"Advanced statistics: Bootstrapping confidence intervals for statistics with \u201cdifficult\u201d distributions","volume":"12","author":"Haukoos","year":"2005","journal-title":"Acad. Emerg. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"General Assembly of the World Medical Association (2014). World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. J. Am. Coll. Dent., 81, 14\u201318.","DOI":"10.1515\/jwiet-2014-0117"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40744-016-0047-x","article-title":"First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study","volume":"3","author":"Schwarting","year":"2016","journal-title":"Rheumatol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3389\/fmed.2020.00303","article-title":"Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents","volume":"7","author":"Wise","year":"2020","journal-title":"Front. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Singh, J.A., Shah, N.P., and Mudano, A.S. (2021). Belimumab for systemic lupus erythematosus. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD010668.pub2"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1136\/annrheumdis-2013-205171","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort","volume":"74","author":"Bruce","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/annrheumdis-2018-214043","article-title":"Organ damage in patients treated with belimumab versus standard of care: A propensity score-matched comparative analysis","volume":"78","author":"Urowitz","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"rkab071","DOI":"10.1093\/rap\/rkab071","article-title":"Health-care utilization and costs in adults with systemic lupus erythematosus in the United Kingdom: A real-world observational retrospective cohort analysis","volume":"5","author":"Samnaliev","year":"2021","journal-title":"Rheumatol. Adv. Pract."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nri2815","article-title":"The X chromosome in immune functions: When a chromosome makes the difference","volume":"10","author":"Libert","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1191\/0961203303lu469xx","article-title":"Epidemiology of systemic lupus erythematosus in a northern Spanish population: Gender and age influence on immunological features","volume":"12","author":"Mozo","year":"2003","journal-title":"Lupus"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13696998.2019.1678170","article-title":"Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States","volume":"23","author":"Kariburyo","year":"2020","journal-title":"J. Med. Econ."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.clinthera.2021.06.009","article-title":"Retrospective Analysis of Disease Severity, Health Care Resource Utilization, and Costs Among Patients Initiating Belimumab for the Treatment of Systemic Lupus Erythematosus","volume":"43","author":"Lokhandwala","year":"2021","journal-title":"Clin. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"AlRuthia, Y., Alrashed, S.A., Balkhi, B., Aljamal, M.S., Alsifri, S., Alrumaih, A.M., Alsabaan, F., Alsaqa\u2019aby, M., Al-Abdulkarim, H.A., and Altowaijri, A.I. (2020). COVID-19 and Saudi Arabia public financing of prescription drugs: An opportunity for reform. Health Policy Technol.","DOI":"10.1016\/j.hlpt.2020.10.008"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archdermatol.2010.435","article-title":"Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus","volume":"147","author":"Klein","year":"2011","journal-title":"Arch. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e000176","DOI":"10.1136\/lupus-2016-000176","article-title":"Use of SLICC criteria in a large, diverse lupus registry enables SLE classification of a subset of ACR-designated subjects with incomplete lupus","volume":"4","author":"Aberle","year":"2017","journal-title":"Lupus Sci. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/BOR.0000000000000205","article-title":"Advances in lupus genetics","volume":"27","author":"Niewold","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"820927","DOI":"10.3389\/fphar.2022.820927","article-title":"Genetic Polymorphisms and the Clinical Response to Systemic Lupus Erythematosus Treatment Towards Personalized Medicine","volume":"13","author":"Barliana","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/20\/3\/1917\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:11:49Z","timestamp":1760119909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/20\/3\/1917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijerph20031917"],"URL":"https:\/\/doi.org\/10.3390\/ijerph20031917","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]}}}